EnBiotix, Inc. announced that it has received $11 million in a round of funding on December 29, 2021. The transaction included participation from Vectura Group plc, Cystic Fibrosis Foundation, and returning investor Sanford Biosciences LLC. The company issued convertible note in the transaction.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0624 CHF | -1.89% | -2.19% | +52.20% |
01/05 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
17/04 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+52.20% | 4.75M | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-15.40% | 31.87B | |
+53.93% | 24.52B | |
-14.35% | 15.68B | |
-39.65% | 12.23B | |
-6.52% | 12.34B | |
-13.41% | 12.21B | |
+6.22% | 8.83B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation